PFE Pfizer, Inc. Common Stock

32.14
+0.02  (0%)
Previous Close 32.12
Open 32.12
Price To book 3.28
Market Cap 191.81B
Shares 5,967,844,000
Volume 17,568,456
Short Ratio 3.45
Av. Daily Volume 22,424,200

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 CROWN trial initiated April 2017.Regulatory filing due 2H 2017.
Lorlatinib
ALK+ NSCLC
Approval announced May 9, 2017.
Avelumab
Urothelial Carcinoma
Priority review announced February 21, 2016. Estimate PDUFA date August 21, 2017 at latest. Possibly earlier as NDA acceptance was announced following 3-day weekend.
Inotuzumab Ozogamicin
Relapsed or Refractory Acute Lymphoblastic Leukemia in Adults
Phase 3 trial initiated March 2017.
PF-06425090
C. difficile Infection
Phase 3 ongoing. Estimate data 2020 using clinicaltrials.gov data.
XTANDI
Metastatic hormone sensitive prostate cancer
Phase 3 trial terminated - noted May 17, 2017.
XTANDI (ENDEAR)
Triple negative breast cancer
Phase 3 ongoing. Estimate data 1H 2021 using clinicaltrials.gov data.
XTANDI (EMBARK)
Non-metastatic high risk hormone-sensitive prostate cancer
Phase 3 completed. Regulatory filing due 1H 2017.
Xeljanz
Ulcerative colitis
PDUFA date December 31, 2017. No exact date given. December 31, 2017 noted as last possible date using guidance of "December 31".
Xeljanz
Psoriatic arthritis
Phase 3 ongoing. Estimate data due late 2017 or early 2018 using clinicaltrials.gov data.
Tanezumab
Chronic low back pain
Phase 3 ongoing. Estimate data due 2018 using clinicaltrials.gov data.
Tanezumab
Cancer pain
Phase 3 ongoing. Estimate data late 2017 or early 2018 using clinicaltrials.gov data.
Tanezumab
Osteoarthritis
Phase 3 data due January 2018.
Talazoparib
BRCA-mutated breast cancer
Phase 3 primary endpoint met - July 2016.
Sutent (Sunitinib)
Renal cell carcinoma (RCC)
Phase 3 trial met primary endpoint - December 2016.
LYRICA (pregabalin)
Pediatric Epilepsy
Phase 3 data released December 30, 2016 - primary endpoint not met.
hGH-CTP (MOD-4023)
Adults - growth hormone deficiency
Phase 3 initiation announced December 30, 2016.
hGH-CTP (MOD-4023)
Children - growth hormone deficiency
PDUFA date set for December 2017 - exact date not provided. December 31 entered as latest possible date for calendar entry purposes only.
Ertugliflozin
Type 2 diabetes
Phase 3 initiated June 2015. Enrollment to be completed 2H 2018.
GMI-1070 (rivipansel)
Vaso-occlusive crisis of sickle cell disease
Phase 3 trial met primary endpoint - December 2016.
BOSULIF (BFORE)
First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Priority review announced November 29, 2016. Approval announced March 23, 2017.
Avelumab
Metastatic Merkel cell carcinoma
sNDA acceptance announced December 21, 2016. Approval announced March 31, 2017.
IBRANCE (palbociclib)
HR+, HER2- Metastatic Breast Cancer

Latest News

  1. Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Corporation
  2. The Current State Of The Breast Cancer Treatment Space
  3. Merck & Co Faces Financial Hit From U.K. Regulator Over Drug Pricing
  4. The 3 Best Dividend Stocks in Arthritis Medication
  5. 3 Ways Johnson & Johnson's Pharmaceutical Business Plans to Beat the Market
  6. 3 Stocks to Supplement Your Social Security Income
  7. [$$] Iterum Therapeutics Lines Up Funding Ahead of Trials
  8. ETFs with exposure to Pfizer Inc. : May 19, 2017
  9. Billionaire George Soros Is Warming Up to This Big Pharma Stock. Should You?
  10. CHMP backs Novartis's Zykadia for first-line use in lung cancer
  11. Conference Spotlights Drug Giant Donnybrooks In Cancer Treatments
  12. Pfizer Inc. :PFE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 18, 2017
  13. The Zacks Analyst Blog Highlights: Pfizer, Home Depot, ConocoPhillips, Prudential Financial and Canadian Pacific
  14. The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis
  15. A Doomed Trump Presidency Would Be a Terrifying Development for Pharmaceutical Stocks
  16. [$$] Some Biotech Companies Making the Cut in Narrower IPO Market
  17. Pfizer Oncology to Present Data Across 13 Different Types of Cancer at ASCO 2017 Annual Meeting
  18. Astellas Announces Oncology Portfolio Updates
  19. Pfizer drug from Medivation deal shows promise in breast cancer -study
  20. Stock Market Today & Home Depot, Pfizer and ConocoPhillips Research Reports